TP53 Gene Alterations including Codon 72 Polymorphism in Patients with Multiple Myeloma

Introduction: Multiple Myeloma (MM) is a cytogenetically heterogeneous haematologic malignancy characterised by uncontrolled proliferation of clonal plasma cells within the bone marrow. TP53 gene inactivation is considered as an independent prognostic marker and patients harbouring these mutations a...

Full description

Bibliographic Details
Main Authors: Perumal Govindasamy, Charles Sharchil, Nithya Mohan, Prabu Pandurangan, Anil Tarigopula, Rama Mani, Chandra R Samuel
Format: Article
Language:English
Published: JCDR Research and Publications Private Limited 2018-02-01
Series:Journal of Clinical and Diagnostic Research
Subjects:
Online Access:https://jcdr.net/articles/PDF/11170/34222_CE[Ra1]_F(SHU)_PF1_(PB_BT_RA_SL)_PFA_(MJ_SL)_PN(SL).pdf
id doaj-414c35c134a6496a899223abf66b5054
record_format Article
spelling doaj-414c35c134a6496a899223abf66b50542020-11-25T02:05:23ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2018-02-01122GC01GC0510.7860/JCDR/2018/34222.11170TP53 Gene Alterations including Codon 72 Polymorphism in Patients with Multiple MyelomaPerumal Govindasamy0Charles Sharchil1Nithya Mohan2Prabu Pandurangan3Anil Tarigopula4Rama Mani5Chandra R Samuel6Senior Technical Officer, Department of Centralised Molecular Diagnostics, Apollo Hospitals, Chennai, Tamil Nadu, India.UGC-UPE Project Fellow, Department of Genetics, Dr. AL Mudaliar PG Institute of Basic Medical Sciences, University of Madras, Chennai, Tamil Nadu, India.UGC-MRP Project Fellow, Department of Genetics, Dr. AL Mudaliar PG Institute of Basic Medical Sciences, University of Madras, Chennai, Tamil Nadu, India.Senior Consultant Haematologist, Department of Haematology, Apollo Hospitals, Chennai, Tamil Nadu, India.Consultant Pathologist, Department of Centralised Molecular Diagnostics, Apollo Hospitals, Chennai, Tamil Nadu, India.Senior Consultant Pathologist and Head, Department of Centralised Molecular Diagnostics, Apollo Hospitals, Chennai, Tamil Nadu, India.Associate Professor (Retd.), Department of Genetics, Dr. AL Mudaliar PG Institute of Basic Medical Sciences, University of Madras, Chennai, Tamil Nadu, India.Introduction: Multiple Myeloma (MM) is a cytogenetically heterogeneous haematologic malignancy characterised by uncontrolled proliferation of clonal plasma cells within the bone marrow. TP53 gene inactivation is considered as an independent prognostic marker and patients harbouring these mutations are usually resistant to standard therapy. Aim: To determine the frequency of TP53 gene mutations in exons 4 to 9 and the distribution of Arg72Pro polymorphism in exon 4 in newly diagnosed multiple myeloma patients. Materials and Methods: Mutation analysis of genomic DNA from unsorted bone marrow aspirates of 30 patients (10 showed TP53 deletion by interphase FISH) and from peripheral blood lymphocytes of 30 healthy control individuals was performed by direct sequencing of amplified products using self-designed primers. The codon 72 polymorphism was studied using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) technique in an additional 108 MM patients and 70 healthy controls. Results: TP53 gene alterations were recorded in six patients (20%) and three of them showed two or more changes. No alterations were observed in exons 5, 7 and 9 in myeloma patients. Four mutations in codons c.284C>T (exon 4), c.641A>G (exon 6), c.787A>G and c.808T>G (exon 8) and three intronic variants c.672+48G>A (intron 6), c.782+72C>T and c.782+92T>G (intron 7) were seen only in the patient group. The variants c.108G>A (exon 4), c.672+62A>G (intron 6) and c.993+12T>C (intron 9) were observed in both groups. Three patients died within six months of diagnosis. The genotype and allele frequencies for Arg72Pro polymorphism were similar in the patient and in the control groups. Conclusion: The presence of TP53 mutations denoted a poor prognosis while the TP53 Pro72Arg polymorphism is not associated with increased risk for MM.https://jcdr.net/articles/PDF/11170/34222_CE[Ra1]_F(SHU)_PF1_(PB_BT_RA_SL)_PFA_(MJ_SL)_PN(SL).pdfarg72pro polymorphismdel(17p)tp53 mutations
collection DOAJ
language English
format Article
sources DOAJ
author Perumal Govindasamy
Charles Sharchil
Nithya Mohan
Prabu Pandurangan
Anil Tarigopula
Rama Mani
Chandra R Samuel
spellingShingle Perumal Govindasamy
Charles Sharchil
Nithya Mohan
Prabu Pandurangan
Anil Tarigopula
Rama Mani
Chandra R Samuel
TP53 Gene Alterations including Codon 72 Polymorphism in Patients with Multiple Myeloma
Journal of Clinical and Diagnostic Research
arg72pro polymorphism
del(17p)
tp53 mutations
author_facet Perumal Govindasamy
Charles Sharchil
Nithya Mohan
Prabu Pandurangan
Anil Tarigopula
Rama Mani
Chandra R Samuel
author_sort Perumal Govindasamy
title TP53 Gene Alterations including Codon 72 Polymorphism in Patients with Multiple Myeloma
title_short TP53 Gene Alterations including Codon 72 Polymorphism in Patients with Multiple Myeloma
title_full TP53 Gene Alterations including Codon 72 Polymorphism in Patients with Multiple Myeloma
title_fullStr TP53 Gene Alterations including Codon 72 Polymorphism in Patients with Multiple Myeloma
title_full_unstemmed TP53 Gene Alterations including Codon 72 Polymorphism in Patients with Multiple Myeloma
title_sort tp53 gene alterations including codon 72 polymorphism in patients with multiple myeloma
publisher JCDR Research and Publications Private Limited
series Journal of Clinical and Diagnostic Research
issn 2249-782X
0973-709X
publishDate 2018-02-01
description Introduction: Multiple Myeloma (MM) is a cytogenetically heterogeneous haematologic malignancy characterised by uncontrolled proliferation of clonal plasma cells within the bone marrow. TP53 gene inactivation is considered as an independent prognostic marker and patients harbouring these mutations are usually resistant to standard therapy. Aim: To determine the frequency of TP53 gene mutations in exons 4 to 9 and the distribution of Arg72Pro polymorphism in exon 4 in newly diagnosed multiple myeloma patients. Materials and Methods: Mutation analysis of genomic DNA from unsorted bone marrow aspirates of 30 patients (10 showed TP53 deletion by interphase FISH) and from peripheral blood lymphocytes of 30 healthy control individuals was performed by direct sequencing of amplified products using self-designed primers. The codon 72 polymorphism was studied using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) technique in an additional 108 MM patients and 70 healthy controls. Results: TP53 gene alterations were recorded in six patients (20%) and three of them showed two or more changes. No alterations were observed in exons 5, 7 and 9 in myeloma patients. Four mutations in codons c.284C>T (exon 4), c.641A>G (exon 6), c.787A>G and c.808T>G (exon 8) and three intronic variants c.672+48G>A (intron 6), c.782+72C>T and c.782+92T>G (intron 7) were seen only in the patient group. The variants c.108G>A (exon 4), c.672+62A>G (intron 6) and c.993+12T>C (intron 9) were observed in both groups. Three patients died within six months of diagnosis. The genotype and allele frequencies for Arg72Pro polymorphism were similar in the patient and in the control groups. Conclusion: The presence of TP53 mutations denoted a poor prognosis while the TP53 Pro72Arg polymorphism is not associated with increased risk for MM.
topic arg72pro polymorphism
del(17p)
tp53 mutations
url https://jcdr.net/articles/PDF/11170/34222_CE[Ra1]_F(SHU)_PF1_(PB_BT_RA_SL)_PFA_(MJ_SL)_PN(SL).pdf
work_keys_str_mv AT perumalgovindasamy tp53genealterationsincludingcodon72polymorphisminpatientswithmultiplemyeloma
AT charlessharchil tp53genealterationsincludingcodon72polymorphisminpatientswithmultiplemyeloma
AT nithyamohan tp53genealterationsincludingcodon72polymorphisminpatientswithmultiplemyeloma
AT prabupandurangan tp53genealterationsincludingcodon72polymorphisminpatientswithmultiplemyeloma
AT aniltarigopula tp53genealterationsincludingcodon72polymorphisminpatientswithmultiplemyeloma
AT ramamani tp53genealterationsincludingcodon72polymorphisminpatientswithmultiplemyeloma
AT chandrarsamuel tp53genealterationsincludingcodon72polymorphisminpatientswithmultiplemyeloma
_version_ 1724938329466601472